Datapoint: UCB to Acquire Zogenix

Biopharma company UCB last week entered a deal to acquire Zogenix, the manufacturer of epilepsy drug Fintepla. For the treatment of epilepsy, Fintepla holds covered or better status for 87% of all insured lives under the pharmacy benefit. 11% of all covered lives have preferred access to Fintepla.

SOURCE: MMIT Analytics, as of 1/24/22

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 20

Datapoint: FDA Expands Otezla’s Psoriasis Label

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 16

Datapoint: Cigna, Oscar to End Small Group Partnership

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 15

Datapoint: FDA Approves Pfizer’s Hemophilia B Treatment

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today